BioSig Technologies Inc. (NASDAQ:BSGM) shares traded 12.06% higher at $0.83 on Wall Street last session.
As we calculate the median target price by taking the range between a high of $6.00 and a low of $1.50, we find $3.75. Given the previous closing price of $0.74, this indicates a potential upside of 406.76 percent. BSGM stock price is now 69.48% away from the 50-day moving average and 14.85% away from the 200-day moving average. The market capitalization of the company currently stands at $45.93M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Brokers who have rated the stock have averaged $3.75 as their price target over the next twelve months.
With the price target of $9, ROTH Capital recently initiated with Buy rating for BioSig Technologies Inc. (NASDAQ: BSGM).
In other news, Sieckhaus John, Chief Operating Officer bought 5,000 shares of the company’s stock on Sep 12. The stock was bought for $4,550 at an average price of $0.91. Upon completion of the transaction, the Chief Operating Officer now directly owns 70,000 shares in the company, valued at $58100.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 09, Chief Executive Officer LONDONER KENNETH L bought 29,700 shares of the business’s stock. A total of $24,299 was incurred on buying the stock at an average price of $0.82. This leaves the insider owning 1,896,820 shares of the company worth $1.57 million. A total of 7.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BSGM stock. A new stake in BioSig Technologies Inc. shares was purchased by TRUIST FINANCIAL CORP during the first quarter worth $148,000. CITADEL ADVISORS LLC invested $18,000 in shares of BSGM during the first quarter. In the first quarter, KERBERROSE WEALTH MANAGEMENT, LLC acquired a new stake in BioSig Technologies Inc. valued at approximately $13,000. TWO SIGMA SECURITIES, LLC acquired a new stake in BSGM for approximately $10,000. ROYAL BANK OF CANADA purchased a new stake in BSGM valued at around $2,000 in the second quarter. In total, there are 55 active investors with 9.50% ownership of the company’s stock.
BioSig Technologies Inc. (NASDAQ: BSGM) opened at $0.7400 on Tuesday. During the past 12 months, BioSig Technologies Inc. has had a low of $0.25 and a high of $1.91. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.20, and a quick ratio of 0.60. The fifty day moving average price for BSGM is $0.4897 and a two-hundred day moving average price translates $0.7227 for the stock.
The latest earnings results from BioSig Technologies Inc. (NASDAQ: BSGM) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.15, beating analysts’ expectations of -$0.19 by 0.04. This compares to -$0.21 EPS in the same period last year. The company reported revenue of $0.14 million for the quarter, compared to $0.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.0 percent. For the current quarter, analysts expect BSGM to generate $140k in revenue.
BioSig Technologies Inc.(BSGM) Company Profile
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
